Filtered By:
Specialty: Research
Condition: Bleeding
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 130 results found since Jan 2013.
Synthesis and Evaluation of a Novel Nanoparticle Carrying Urokinase Used in Targeted Thrombolysis.
This article is protected by copyright. All rights reserved.
PMID: 31581363 [PubMed - as supplied by publisher]
Source: Biomed Res - October 2, 2019 Category: Research Authors: Zhong Y, Gong WJ, Gao XH, Li YN, Liu K, Hu YG, Qi JS Tags: J Biomed Mater Res A Source Type: research
Reasons for discontinuation of novel oral anticoagulant therapy in patients with atrial fibrillation.
Conclusion: DOAC discontinuation rates varied significantly and appeared related to drug-specific side effects, patient-initiated discontinuation, and bleeding. We observed longer-term administration of apixaban, suggesting that this drug is better tolerated than dabigatran or rivaroxaban.
PMID: 32011180 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 5, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Obese Nonvalvular Atrial Fibrillation Patients: Analysis of Electronic Health Record Data.
Conclusions: Among obese NVAF patients, prescription of rivaroxaban was associated with a reduced risk of SSE and major bleeding compared to warfarin, which remained consistent across BMI classes.
PMID: 32347755 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 1, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research
Minor bleeding in patients with atrial fibrillation using a non-vitamin K antagonist oral anticoagulant.
Conclusion: Our data showed that minor bleeds are common in novel NOAC users, especially when using apixaban and rivaroxaban. In the latter two NOACs, hematoma (bruises) and nose bleeds were more frequently observed and accounted for the difference with dabigatran. Besides type of NOAC, a higher HAS-BLED score and novel anticoagulant drug use were associated with an increased risk of minor bleeding.
PMID: 32573287 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 24, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research
Low-dose thrombolysis for submassive pulmonary embolism
This study aimed to evaluate the role of half-dose tissue-type plasminogen activator (rt-PA) in preventing death/hemodynamic decompensation in submassive (intermediate-risk) PE without increasing the risk of bleeding. In a prospective, non-randomized, open-label, single-center trial, we compared 50 mg rt-PA plus low molecular weight heparin (LMWH) with LMWH in submassive (intermediate-risk) PE. Eligible cases had confirmed pulmonary hypertension on echocardiography, and/or right ventricular cavity expansion and/or interventricular septal deviation on echocardiography, and/or right to left ventricular ratio equal to or grea...
Source: Journal of Investigative Medicine - November 25, 2021 Category: Research Authors: Yilmaz, E. S., Uzun, O. Tags: Open access Original research Source Type: research
A Nomogram Model for Predicting Type-2 Myocardial Infarction Induced by Acute Upper Gastrointestinal Bleeding
ConclusionThe nomogram was proven to be a useful tool for the risk stratification of T2MI in AUGIB patients, and is helpful for the early identification of AUGIB patients who are prone to T2MI for early intervention, especially in emergency departments and intensive care units.
Source: Journal of Huazhong University of Science and Technology -- Medical Sciences -- - March 15, 2022 Category: Research Source Type: research
A Cohort Study on the Safety and Efficacy of Warfarin and Rivaroxaban in Anticoagulant Therapy in Patients with Atrial Fibrillation Study
CONCLUSION: Compared with warfarin, rivaroxaban anticoagulant therapy has the same advantage in tolerance and prevention of thromboembolism in patients with AF, but rivaroxaban can effectively reduce the risk of bleeding in patients with AF.PMID:35845939 | PMC:PMC9283039 | DOI:10.1155/2022/4611383
Source: Biomed Res - July 18, 2022 Category: Research Authors: Li Wang Wentao Yao Source Type: research
Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19
CONCLUSION: NVAF patients with COVID-19 who discontinued apixaban had a higher risk of hospitalization and thrombotic events vs. those who continued apixaban, with no significant difference in bleeding-related hospitalization.PMID:36000258 | DOI:10.1080/03007995.2022.2112871
Source: Current Medical Research and Opinion - August 24, 2022 Category: Research Authors: Steven Deitelzweig Julia Zhu Jenny Jiang Xuemei Luo Allison Keshishian Mauricio Ferri Lisa Rosenblatt Patricia Schuler Cynthia Gutierrez Amol D Dhamane Source Type: research
Comparison of ketamine/xylazine and isoflurane anesthesia on the establishment of mouse middle cerebral artery occlusion model
In conclusion, compared with ISO anesthesia, KX anesthesia is a safer and more suitable method for the establishment of a mouse MCAO model. The data will inform safer and more detailed anesthesia recommendations for the establishment of animal models of vascular-related major injury diseases.PMID:36418078 | DOI:10.1538/expanim.22-0131
Source: Experimental Animals - November 23, 2022 Category: Research Authors: Chenyang Gu Jiale Liu Yajing Li Qiankun Zhang Chaoqun Lin Jiajun Huang Wenjie Duan Yushu Deng Waqas Ahmed Rong Li Jun Long Ahsan Ali Khan Lukui Chen Source Type: research
Therapeutic effect of antithrombotic drug combinations in patients with atrial fibrillation undergoing percutaneous coronary intervention for coronary heart disease: a meta-analysis
CONCLUSIONS: DAT with NOACs has a higher safety profile against bleeding in patients with atrial fibrillation after PCI. DAT with VKAs was similar to TAT in terms of antithrombotic effect and incidence of bleeding.PMID:36628223 | PMC:PMC9827321
Source: American Journal of Translational Research - January 11, 2023 Category: Research Authors: Huabin He Xifeng Xiao Xiangyang Yuan Jianhai Chen Source Type: research
